Why carry out this study?

Our aim was to compare the effectiveness of pro re nata (PRN) and treat-and-extend (T&E) regimens in treating neovascular age-related macular degeneration (nAMD) using real-world data, addressing gaps in existing clinical practice evidence.

We sought to identify optimal anti-vascular endothelial growth (VEGF) treatment regimens, addressing the balance between treatment efficacy and the burden on patients and healthcare systems.

What was learned from this study?

The T&E regimen showed superior visual acuity improvement over 24 months (+ 4.2 vs. + 1.3 logMAR letters, p < 0.001) compared to PRN, with more injections (15 vs. 10 mean injections).

These results are significant for guiding clinical decisions and optimizing treatment approaches, considering both the clinical efficacy and the implications for health policy and economics.